These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 5444978)

  • 1. Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).
    Bergqvist N
    Acta Med Scand; 1970 Mar; 187(3):213-8. PubMed ID: 5444978
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical trial of C.P.I.B. (clofibrate) in treatment of diabetic hypertriglyceridemia].
    Warembourg H; Jaillard J
    Lille Med; 1968 Jan; 13(1):Suppl:5-8. PubMed ID: 5745605
    [No Abstract]   [Full Text] [Related]  

  • 3. [Arteriosclerosis--nicotinic acid therapy. 10. Combination therapy in hyperlipemia].
    Hansen PF
    Lakartidningen; 1971 Apr; 68(15):1769-72. PubMed ID: 5577252
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clofibrate in the treatment of diabetes mellitus].
    Bornemisza P; Csögör I
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1978; 30(4):359-62. PubMed ID: 30153
    [No Abstract]   [Full Text] [Related]  

  • 5. [Serum-lipid reducing principles--possibilities for treatment. 6. Indications for the use of clofibrate].
    Gustafson A
    Lakartidningen; 1970 Dec; 67():Suppl IV:75+. PubMed ID: 5511954
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of essential hypercholesterolemia with clofibrate and nicotinic acid.
    Nordoy A; Gjone E
    Acta Med Scand; 1970 Dec; 188(6):487-90. PubMed ID: 5494813
    [No Abstract]   [Full Text] [Related]  

  • 7. [The treatment of essential hyperlipidemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
    [No Abstract]   [Full Text] [Related]  

  • 8. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet function and platelet phospholipids in patients with hyperbetalipoproteinemia. Effect of nicotinic acid and clofibrate.
    Nordoy A; Rodset JM
    Acta Med Scand; 1971 May; 189(5):385-9. PubMed ID: 5578488
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term monitoring during clofibrate therapy.
    Vester JW; Sunder JH; Aarons JH; Danowski TS
    Clin Pharmacol Ther; 1970; 11(5):689-97. PubMed ID: 5460240
    [No Abstract]   [Full Text] [Related]  

  • 11. [Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)].
    Wahl P; Hasslacher C; Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1978 Aug; 103(31):1233-7. PubMed ID: 668570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of essential hyperlipemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jun; 24(12):184-7. PubMed ID: 5404292
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of fenofibrate and clofibrate hypolipidemic effects.
    Daubresse JC
    Acta Clin Belg; 1980; 35(4):227-32. PubMed ID: 7015771
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical, biochemical and pathological studies of long term "clofibrate" therapy.
    el-Mehairy MM; Attia O; Nabih AE; Nassar I; Ibrahim WN
    J Trop Med Hyg; 1970 Jul; 73(7):177-81. PubMed ID: 5470220
    [No Abstract]   [Full Text] [Related]  

  • 15. [Blood lipid balance in simple diabetes mellitus or diabetes with excess weight, in relation to age and sex (epidemiological study)].
    Mincu I; Câmpeanu S; Dumitrescu C; Mihalache N; Ionescu D
    Med Interna (Bucur); 1971 Dec; 23(12):1455-70. PubMed ID: 5159282
    [No Abstract]   [Full Text] [Related]  

  • 16. [Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia. Behavior of plasma lipids, glucose tolerance, and plasma insulin after glucose load during treatment with clofibrate].
    Bruns W; Rjasanowski I; Wulfert P; Michael R; Knospe S; Hildmann W
    Endokrinologie; 1974 Nov; 64(1):2-12. PubMed ID: 4466653
    [No Abstract]   [Full Text] [Related]  

  • 17. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type IIa hyperlipoproteinaemia. An evaluation of four therapeutic regimens.
    Watermeyer GS; Mann JI; Truswell AS; Levy I
    S Afr Med J; 1975 Apr; 49(15):631-4. PubMed ID: 1094562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with an antilipemic agent, ethylchlorophenoxyisobutyrate].
    Noleto PA; de Bulhões F; Tuma M
    Rev Bras Med; 1969 Oct; 26(10):602-5. PubMed ID: 5404870
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary observations of fasting glucose, triglyceride, and cholesterol levels in Mulago Hospital Diabetic Clinic.
    Otim MA; Kyobe J
    East Afr Med J; 1977 Feb; 54(2):96-9. PubMed ID: 885094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.